A Cancer Research UK Phase I dose escalation trial of oral VEGFR and EGFR inhibitor, Vandetanib in combination with the oral MEK inhibitor, Selumetinib (VanSel-1) in solid tumours (dose escalation) and NSCLC (expansion cohort)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Selumetinib (Primary) ; Vandetanib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms VanSel1
- 13 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 13 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress